160 related articles for article (PubMed ID: 36931700)
61. Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.
Zhang L; Zhou R; Zhang W; Yao X; Li W; Xu L; Sun X; Zhao L
J Exp Clin Cancer Res; 2019 Mar; 38(1):120. PubMed ID: 30850009
[TBL] [Abstract][Full Text] [Related]
62. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
63. The novel circSLC6A6/miR-1265/C2CD4A axis promotes colorectal cancer growth by suppressing p53 signaling pathway.
Rong Z; Luo Z; Fu Z; Zhang P; Li T; Zhang J; Zhu Z; Yu Z; Li Q; Qiu Z; Huang C
J Exp Clin Cancer Res; 2021 Oct; 40(1):324. PubMed ID: 34656159
[TBL] [Abstract][Full Text] [Related]
64. The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex.
Feng Y; Longmore GD
Mol Cell Biol; 2005 May; 25(10):4010-22. PubMed ID: 15870274
[TBL] [Abstract][Full Text] [Related]
65. P53-induced MRVI1 mediates carcinogenesis of colorectal cancer.
Ma L; Wang H; Sun Y; Yang D; Pu L; Zhang X
Scand J Gastroenterol; 2020 Jul; 55(7):824-833. PubMed ID: 32589066
[No Abstract] [Full Text] [Related]
66. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling.
Zhang C; Liu J; Wang X; Wu R; Lin M; Laddha SV; Yang Q; Chan CS; Feng Z
Oncotarget; 2014 Oct; 5(19):9106-17. PubMed ID: 25193859
[TBL] [Abstract][Full Text] [Related]
67. LIM protein Ajuba promotes liver cell proliferation through its involvement in DNA replication and DNA damage control.
Dommann N; Gavini J; Sánchez-Taltavull D; Baier FA; Birrer F; Loforese G; Candinas D; Stroka D
FEBS Lett; 2022 Jul; 596(14):1746-1764. PubMed ID: 35535434
[TBL] [Abstract][Full Text] [Related]
68. P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.
Gunasegaran B; Neilsen PM; Smid SD
Toxicol In Vitro; 2020 Sep; 67():104908. PubMed ID: 32502622
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
70. The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF-κB signalling function.
Sultana MA; Cluning C; Kwong WS; Polain N; Pavlos NJ; Ratajczak T; Walsh JP; Xu J; Rea SL
PLoS One; 2021; 16(11):e0259556. PubMed ID: 34735553
[TBL] [Abstract][Full Text] [Related]
71. Knockout of Ajuba Attenuates the Growth and Migration of Hepatocellular Carcinoma Cells.
Le Y; He Y; Bai M; Wang Y; Wu J; Yu L
Cytogenet Genome Res; 2020; 160(11-12):650-658. PubMed ID: 33640888
[TBL] [Abstract][Full Text] [Related]
72. FOXD3, frequently methylated in colorectal cancer, acts as a tumor suppressor and induces tumor cell apoptosis under ER stress via p53.
Xu M; Zhu J; Liu S; Wang C; Shi Q; Kuang Y; Fang X; Hu X
Carcinogenesis; 2020 Sep; 41(9):1253-1262. PubMed ID: 31784734
[TBL] [Abstract][Full Text] [Related]
73. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.
Thorenoor N; Faltejskova-Vychytilova P; Hombach S; Mlcochova J; Kretz M; Svoboda M; Slaby O
Oncotarget; 2016 Jan; 7(1):622-37. PubMed ID: 26506418
[TBL] [Abstract][Full Text] [Related]
74. Identification of genes with universally upregulated or downregulated expressions in colorectal cancer.
Song K; Su W; Liu Y; Zhang J; Liang Q; Li N; Guan Q; He J; Bai X; Zhao W; Guo Z
J Gastroenterol Hepatol; 2019 May; 34(5):880-889. PubMed ID: 30395690
[TBL] [Abstract][Full Text] [Related]
75. MDM2/p53 protein expression in the development of colorectal adenocarcinoma.
Abdel-Fattah G; Yoffe B; Krishnan B; Khaoustov V; Itani K
J Gastrointest Surg; 2000; 4(1):109-14. PubMed ID: 10631371
[TBL] [Abstract][Full Text] [Related]
76. The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells.
Bai Z; Wang J; Wang T; Li Y; Zhao X; Wu G; Yang Y; Deng W; Zhang Z
Cell Physiol Biochem; 2017; 44(5):1882-1895. PubMed ID: 29224019
[TBL] [Abstract][Full Text] [Related]
77. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Giovannetti E; Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Poupon MF; Azzarello A; Pinedo HM; Peters GJ
Br J Cancer; 2007 Mar; 96(5):769-75. PubMed ID: 17339891
[TBL] [Abstract][Full Text] [Related]
78. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
[TBL] [Abstract][Full Text] [Related]
79. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
80. Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Al-Khayal K; Abdulla M; Al-Obeed O; Al Kattan W; Zubaidi A; Vaali-Mohammed MA; Alsheikh A; Ahmad R
Oncol Rep; 2016 Mar; 35(3):1281-6. PubMed ID: 26675982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
